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The efficiency of retinoic acid (RA)-Induced differentiation was dependent on the position of HL-60 cells in the cell cycle. Our results demonstrated 
that cells at the G,/S border were more efficiently induced to differentiate by short exposure to RA than cells at other phases of the cell cycle. 
Synchromzation of cells m GJS phase by aphidicolin (APH) or mimosine (MIMO) increased the sensitivity of cells to RA short exposure treatment. 
Pretreatment with sphinganine (SP). a protein kinase C (PKC) Inhibitor, potentiated RA-induced cell differentiation. By cell cycle analysis, SP was 
found to block the cell progression through the GJS phase. Consequently, cells accumulated in the GJS phase of the cell cycle. The present data 
therefore suggest a possible mechanism of action of SP to enhance RA-induced differentiation. 
Cell cycle; Granulocytic differentiation; Retinoic acid; Sphinganine 
1. INTRODUCTION 
The retinoids, and in particular, retinoic acid (RA), 
exert a wide range of biological effects related to cell 
proliferation and differentiation (see [l] for review). 
Human promyelocytic leukemia HL-60 cells can be in- 
duced to differentiate along the granulocytic pathway 
by RA [2]. Although the mechanism of RA action re- 
mains unclear, there is some evidence suggesting that 
RA acts at the cell surface [3] or interacts with a nuclear 
RA receptor (RAR) family [4-61. In general, the anti- 
proliferative activity of RA is a reversible phenomenon 
[7,8]. Therefore, in the management of cancer disease, 
RA is usually used in combination with other inducers 
[9-131 to facilitate the RA-induced differentiation. Pre- 
viously, Stevens et al. [13] have shown that sphinganine 
(SP), a potent inhibitor of protein kinase C (PKC) in 
vitro [14], could potentiate RA-induced differentiation. 
In our previous studies we have also demonstrated that 
pretreatment with SP can modulate the reversibility of 
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the effects induced by brief RA treatment [151. Recently, 
we have shown that the differentiation of HL-60 promy- 
elocytic cells toward mature granulocytic cells induced 
by RA was accompanied by a decrease in PKC activity 
[ 161. The enhancement of RA-induced differentiation 
and the potentiation of the decrease of PKC activity by 
SP seemed to correlate with each other [16]. However, 
the precise mechanism of action of this sphingolipid 
long-chain base in the potentiation of RA-induced dif- 
ferentiation is still presently unclear. 
Gezer et al. have demonstrated that the growth frac- 
tion of HL-60 cells is decreased and the total cell cycle 
time is prolonged during cellular differentiation in re- 
sponse to RA [ 171. This is a result of the lengthening of 
both G, and S phases in the cells [17]. Moreover, in- 
duced differentiation of transformed cells has been 
shown to be associated with modulation of expression 
of a number of gene products such as some protoonco- 
genes c-myb, c-myc, c-fos and ~53 [18-231, that appear 
to be involved in the control of cell cycle progression 
and induction of differentiation. Hence, we believe that 
the cell cycle events could be involved in the RA-in- 
duced differentiation. The present study was therefore 
undertaken to elucidate the cell cycle-dependent effect 
of RA. In this report, we also present studies that ex- 
plore the possible mechanism of action of SP in the 
potentiation of RA-induced maturation of promyelo- 
cytic leukemia cells. Our results showed that cells in 
G,/S border were maximally sensitive to brief RA treat- 
ment while cells in other phases of the cell cycle were less 
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sensitive. Our results also showed that the potentiation 
of the RA-induced differentiation by SP pretreatment 
could be rationalized with cell cycle-dependent effect of 
brief RA treatment. SP pretreatment blocked the cell 
progression through GJS phase. SP-pretreated cells 
being blocked at GJS phase were highly responsive to 
brief RA treatment. 
2. MATERIALS AND METHODS 
2.1. Drugs 
Unless otherwise indicated, all chemicals were purchased from 
Sigma Chemical Co. (St. Louis, MO, USA). Aphidicolin (APH) was 
prepared as 1 mg/ml stock solution in 70% ethanol. The stock solu- 
tions of camptothecin (CAM) and nocodazole (ND) were prepared m 
dimethyl sulfoxide (DMSO) at a concentration of 1 mg/ml and 5 
mg/ml, respectively. Mimosine (MIMO) was dissolved in phosphate- 
buffered saline (PBS; 8.5 mM Na*HPO,. 1.6 mM NaH?PO,, 0.145 M 
NaCI, pH 7.2) at a 10 mM concentration. RA, SP and staurosporine 
(ST) were dissolved in ethanol (Merck, Darmstadt, Germany) at 0.002 
M, 0.01 M and 50 ,uM, respectively. Vinblastine (VIN) was obtained 
from David Bull Laboratories (DBL. Victoria, Australia) and was 
dissolved m diluent solution (from DBL) at a 1 mg/ml concentration. 
2.2. Radiochemicals 
[jH]RA (49.3 Cilmmol) was obtained from DuPont New England 
Nuclear (NEN) Co. (Boston. MA, USA). [‘H]Thymldine (25 Ci/ 
mmol) and [‘Hluridine (15-30 Cl/mmol) were purchased from Amer- 
sham (Buckinghamshire, England). 
2.3. CeN culture 
The HL-60 promyelocytic leukemic cells were provided by Dr. Zee 
Fen Chang (Department of Biochemistry, Chang Gung Medical Col- 
lege) and maintained in continuous cultures in our laboratory for three 
years. Cells were grown in suspension in RPMI-1640 medium supple- 
mented with 10% heat-inactivated fetal bovine serum (FBS; JRH 
Biosciences; Lenexa, KS, USA), 2 mM glutamine, 50 units/ml penicil- 
lin and SO&ml streptomycin (Gibco BRL: Gaithersburg. MD. USA) 
in a 5% CO? humidified incubator at 37°C. 
2.4. Cell s.wchromxtlon by serum deprivation 
72 h after the seeding of cells, the medium was removed, cells were 
washed three times with serum-free medium, and HL-60 cells were 
incubated with serum-free medium for 24 h. Under these conditions, 
cells become arrested in a quiescent state. The serum-free medium was 
then removed and replaced with fresh serum-supplied medium. 
2.5. Cell synchronization by chemrcal method 
Exponentially growing cultures containing approximately 1 x 10h 
cells/ml were treated with 300 PM MIMO or 2 &ml APH for 16 h. 
Such treatments resulted in synchronization of over 80% of the cells 
in late G, and G,/S phases, respectively [24]. Treatment ofcells (3 x 10’ 
cells/ml) with 0.1 &ml CAM for 4 h, resulted in having majority of 
the cells arrested in G, phase [25]. Stathmokmetic experiments for M 
phase arrest were done by treating the cultures (2 x IO’ cells/ml) with 
0.05 pg/ml of VIN for 6 h [25] or with 0.5 ,@ml of ND for 12 h. 
2.6. Induction of differentiatron 
In the induction of differentiation. HL-60 cells (2 x 10’ cells/ml) 
were incubated with 1 PM RA. After 2 h of incubation, RA was 
removed (washed three times with PBS) and the differentiation was 
assessed by morphological change (as described below) at day 4 after 
the removal of RA. 
2.7. Wright-Giemsa stain 
Morphological assessment of the induced cells was performed using 
the Wright--Giemsa staining method. Cells (4 x 10“ cells) were pre- 
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pared on slides by Cytospm (Shandon Southern. UK) and stamed with 
Wright-Giemsa stain. The morphology of cells was examined under 
a light microscope (x 1,000). The criteria for the morphological judg- 
ing was according to those previously described [26]. Triphcate 200- 
cell counts were performed. 
2.8. DNA and RNA synthesis rate determmation 
The synthesis rate of DNA was determined by a modification of a 
previously described method [27]. Briefly, cultures were pulsed with 
O.S,&ilml of [‘Hlthymidine 1 h prior to the end of the incubation time. 
Then the cells were harvested and washed three times with 10% trichlo- 
roacetic acid (TCA; Merck) and dissolved in 0.5 ml of 0.25 N NaOH 
and further shaken for 30 min. Ahquots of 300 ~1 were dissolved in 
4 ml of scintillation fluid (Merck) and the radioactivity was measured 
by scintillation counter (Beckman LS5000 TD; Beckman Instruments 
Inc.: Palo Alto, CA, USA). 
The synthesis rate of RNA determination was similar to the DNA 
synthesis rate determination described above. Cells were pulsed with 
0.5 PCilml of [iH]uridine 1 h prior to the end of the incubation time. 
The cells were then washed with 10% TCA and dissolved m I N 
NaOH. Aliquots of 300 ~1 were dissolved in scintillation fluid and 
counted for radioactivlty. 
2.9. CeN cycle analysis 
To estimate the proportions of cells in different phases of the cell 
cycle, cellular DNA contents were measured by flow cytometry as 
described by Ormerod [28]. Briefly. cells (2 x IO6 cells) were fixed by 
70% ethanol (in PBS) in ice for 30 mm and then resuspended m PBS 
containing 40 &ml propidlum iodide (PI) and 0.1 mg/ml RNase 
(Boehringer, Germany). After 30 min at 37°C. 2 x IO” cells were ana- 
lyzed on a FACStar cytofluorometer (Becton-Dickinson: San Jose. 
CA, USA) equipped with an argon-ion laser at 488 nm. 
2.10. Fractionation of HL-60 ceils 
Fractionation of cells was performed as described previously [29]. 
Briefly. the cells were incubated with [‘H]RA for various times before 
0 5 10 15 20 25 30 
Time in complete serum-supplied medium 
(W 
Fig. 1. Cell cycle synchronization ~ [‘Hlthymldine and [‘Hlurldine 
incorporation. HL-60 cells were cultured in 25-cm* plastic tissue flasks 
with serum-free medium for 24 h and then transferred to complete 
serum-supplied medium One hour prior to the end of the incubation 
period, the cells were pulsed with 0.5 &i/ml of [‘Hlthymidine 
(04) or [‘Hlurldine (o--o) for 1 h. Incorporation of these 
radioactive materials into DNA or RNA were assayed as described 
m section 2.8. Each point is the mean t S.D. (n = 3). 
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they were suspended in cold TM buffer (0.01 M Tris-HCI, pH 7.6, 
containing 1 mM MgCl,) and were homogenized 18 strokes with 
all-glass homogenizer (Wheaton, Millville, NJ, USA). The nuclei were 
then collected by centrifugation at 500 x g for 5 min. The supematant 
was further centrifuged at 10,420 x g for 45 min. The final supematant 
(cytosol fraction) and the pellet (membrane fraction) were collected 
separately. The nuclei, cytosol and membrane fractions were resus- 
pended in TM buffer. Each fraction (100 ~1) was then added into 5 
ml scintillation fluor (Merck), and were counted for radioactivity 
(Beckman LSSOOO TD). 
3. RESULTS 
3.1. G,/S phase border cells are maximally sensitive to 
brief RA treatment 
To ensure that the cells were capable of synchro- 
nously re-entering the cell cycle after 24-h serum starva- 
tion, the cells’ abilities of t3H]thymidine and [3H]uridine 
incorporation were determined (Fig. 1). RNA synthesis 
increased immediately and reached its maximum 5 h 
after the cells were transferred to complete serum-sup- 
plied medium. At the same time, the DNA synthesis 
increased slowly and reached its maximum within 10 h. 
The rate of RNA and DNA synthesis declined soon 
after they reached their maximums. The G, phase can 
be confined to the first 2 h. The S phase can then be 
between 4 and 14 h while the G,/M phase is between 15 
to 24 h. The effects of RA on cellular differentiation in 
cells of various phases of cell cycle were then examined. 
As illustrated in Table I, brief RA treatment (1 ,uM, 
2 h) had little effect on induction of differentiation; less 
than 40% of the cells resembled mature granulocytes at 
day 4 after the removal of RA (1 PM; 2 h). Similar 
results were obtained in cells that were briefly treated 
with RA at GJG,, middle S (mid-S), late S or GJM 
phases. Interestingly, cells within the G,/S phase border 
were maximally responsive to RA short exposure (1 
PM; 2 h). Higher percentage of the cells (> 60%) resem- 
bled mature granulocytes at day 4 after the removal of 
RA. This degree of differentiation was similar to the one 
under continuous treatment with 1 ,uM RA (Table I). 
3.2. APH or MIMO-treated cells are highly responsive 
to RA brief treatment 
Furthermore, different cell cycle blockers were ap- 
plied to synchronize cells. The effects of brief RA treat- 
ment on induction of differentiation were determined in 
Table I 
RA-induced differentiation of HL-60 cells in varrous phases of cell cycle 
Time 
after 
transferred 
to serum- 
supplied 
medium 
Cell 
cycle 
phases 
RA 
treatment 
Blast” 
Cell suspension (% of total cells) 
Mature cellsb 
Pro* Myelo” Granulocytes 
Meta” Band Seg 
_‘ _d 2 87 8 3 0 0 
_ _c cone 0 42 46 10 2 0 
_ _c 2 h’ 0 61 26 9 3 1 
0 G, 2 h’ 2 66 20 9 3 0 
1 G, 2 h’ 3 56 30 10 1 0 
2 G,* 2 h’ 0 48 44 8 0 0 
4 early S* 2 h’ 1 38 46 12 2 1 
6 early S* 2 hr 1 50 33 14 2 0 
8 early S 2 h’ 3 57 28 9 3 0 
10 mid-S 2 h’ 1 62 30 5 1 1 
12 late S 2 h’ 0 62 29 4 5 0 
24 G, + M 2 h’ 3 68 24 3 1 1 
HL-60 cells were cultured in 25-cm’ plastic tissue flasks in serum-free medium. Cells (2 x 10’ cells/ml) were then transferred to the complete 
serum-supplied medium after 24 h. At various times (as indicated) of incubation in serum-supplied medium, 1 PM RA was added. After 2 h, the 
drug was removed (washed 3 times with PBS). Differentiation was assessed by morphological changes, as described in section 2.7 at day 4 after 
the removal of RA. 
’ Blast, myeloblast; Pro, promyelocyte; Myelo, myelocyte; Meta, metamyelocyte; Band, banded (stab) neutrophil; Seg, segmented neutrophil. 
Triplicate 200-cell counts were performed. The table is representative of the results obtained in several (at least three) replications of the experiment. 
Viability of the cells was over 90% under these conditions. 
'Assessment of differentiation (myelo, meta, band and seg). 
’ Unsynchronized cells. 
d Control without RA. 
e Continuous RA treatment. 
’ 2 h brief RA treatment. 
*Significantly different from values of 2 h brief RA treatment of unsynchronized cells at P < 0.05 p-test). 
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such drug-treated cells. As shown in Table II, cells after 
treatment with APH (2,f&ml; 16 h) or MIMO (300 ,uM; 
16 h) were highly responsive to RA short exposure. As 
compared to only 3040% of CAM, ND or VIN-treated 
cells being differentiated by brief RA treatment, 55- 
66% of MIMO or APH-treated cells became mature 
granulocytes at day 4 after removal of RA (1 PM; 2 h). 
These results further confirmed that G,/S border cells 
(arrested by MIMO or APH) were highly responsive to 
brief RA treatment while cells in the early G, phase 
(arrested by CAM) or M phase (arrested by VIN or 
ND) were less sensitive to RA short exposure. 
3.3. SP blocks cells in G, and S phases 
As shown previously, the SP pretreatment (2.5 ,LLM, 
24 h) enhanced the RA-induced differentiation [15,16]. 
Higher percentage (> 60%) of SP-pretreated cells resem- 
bled mature granulocytes at day 4 after the removal of 
RA (1 ,uM; 2 h) as compared with non-SP-pretreated 
cells (< 40%) (Table II). In order to understand the 
biological action of SP in potentiation of RA-induced 
differentiation, the effect of SP on cell cycle regulation 
was determined. As shown in the DNA histogram (Fig. 
2) APH- or MIMO-treated cells were blocked in GJS 
phase and G, phase (preferentially late G,), respectively 
(Fig. 2B and C). Similarly, exposure of cells to 2.5 PM 
SP for 24 h resulted in the accumulation of high percent- 
age of cells (> 90%; Fig. 2D) in G,/S phase. Our results 
showed that SP synchronized cells in G,/S phase as 
APH or MIMO did. Being synchronized at G,/S phase, 
SP-pretreated cells were highly sensitive to brief RA 
treatment. Staurosporine (ST), another PKC inhibitor, 
being able to potentiate RA-induced differentiation had 
similar ability to synchronize cells in G,/S phase as SP 
did (data not shown). 
3.4. r3H]RA accumulation and distribution 
To further understand the potentiation of RA-in- 
duced differentiation by GJS blockers, we examined the 
effects of pretreatment with SP, MIMO or APH on the 
accumulation and distribution of [3H]RA in cell nuclei, 
cytosol and membrane during and after brief RA expo- 
sure. Our results showed that there were virtually no 
differences in [3H]RA accumulation nor excretion dur- 
ing and after brief RA exposure in cells treated with or 
without SP, MIMO or APH pretreatment (Fig. 3A). 
Furthermore, [3H]RA that were accumulating or re- 
maining during and after brief RA exposure were in 
majority (> 75%) found in nuclei of cells that had or had 
not been pretreated with SP, MIMO or APH (Fig. 3B 
and C). 
Table II 
Effect of various cell cycle inhibitors on RA-induced differentiation of HL-60 cells 
Cell 
cycle 
Inhibitor 
Blocked at 
various 
cell cycle 
phases 
RA 
treatment 
Blast” 
Cell suspension (% of total cells) 
Mature cell? 
Pro” Myelo” Granulocytes 
Meta” Band” Seg” 
_ 
_ 
_c 2 80 17 1 0 0 
2 h* 0 61 26 9 3 1 
CAM 
MIMO 
APH 
ND 
VIN 
SP 
early G, 2h’ 
late G,* 2h’ 
GJS 2 h’ 
M 2h 
M 2h 
nd* 2h’ 
69 18 9 1 1 
45 32 19 3 1 
34 33 31 I 1 
70 14 14 1 0 
68 20 9 I 0 
36 36 19 4 5 
HL-60 cells were cultured in 25-cm* plastic tissue culture flasks. Cells (2 x 10’ cells/ml) were pretreated with cell cycle blocker (as in section 2.5) 
before 1 PM RA was added to the medium. After 2 h incubation, the drugs were removed (washed 3 times with PBS). Differentiation was assessed 
by morphological change, as described in section 2.7 at day 4 after the removal of drugs. 
a Blast, myeloblast; Pro, promyelocyte; Myelo, myelocyte; Meta, metamyelocyte; Band, banded (stab) neutrophil; Seg, segmented neutrophil. 
Triplicate 200-cell counts were performed. The table is representative of the results obtained in several (at least three) replications ofthe experiment. 
Viability of the cells was over 90% under these conditions. 
‘Assessment of differentiation (myelo, meta, band. and seg). 
c Control without RA nor SP. 
d Control with 2 h brief RA treatment, without other drugs. 
‘2 h brief RA treatment. 
nd. not defined yet. 
*Significantly different from values of control with 2 h brtef RA treatment without other drugs at P < 0.05 ($-test). 
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Fig. 2. Treatment of HL-60 cells with APH, MIMO or SP caused cell cycle arrest at GJS phase. This figure describes the cell cycle distribution 
of untreated control cells (A), or cells treated with APH (2&m]; 16 h) (B), MIMO (300pM; 16 h) (C), or SP (2.5,~M; 24 h)(D). Cells were washed 
free of drugs before aliquots of cells were sampled for flow cytometric analysis. 
4. DISCUSSION 
Three principal controls or transition points are asso- 
ciated with the eukaryotic cell division cycle [30]. These 
are Go to G,, G, to S, and G, to M transitions. The 
elucidation of how these transitions are regulated is of 
fundamental importance in the study of cellular prolif- 
eration and differentiation. The processes in late G, 
prior to S phase (G, to S transition) is called restriction 
(R) point [31]. The R point may contain the ‘switch’ by 
which a variety of signals are turned on. Once past this 
point, cells become committed to the mitotic cell cycle, 
and the alternative developmental fate of conjugation 
cannot take place until the present cell cycle has been 
completed (see [32,33] for review). In this regard, the R 
point (within the G, body) is equivalent o the START 
point (might be at the G,/S border) in yeast cells [32]. 
It is possible that there may be a growth/differentiation 
control signal at GJS border which orders cells to grow 
or to become committed to terminal differentiation. Cell 
cycle prolongation in both G, and S phases were dem- 
onstrated after RA treatment [17]. In this report, we 
have demonstrated that the G,/S border phase is critical 
for RA-induced differentiation. It is suggested that the 
maintenance of G, and S phases might be necessary for 
HL-60 granulocytic differentiation. In parallel, previ- 
ous studies by others have shown that cultured rat and 
mouse myoblasts become committed to myogenesis 
only in the G, phase of the cell cycle [34,35]. Further- 
more, embryonal carcinoma (EC) P19 cells are induced 
to differentiate by RA only if the cells are in G1 phase 
during drug exposure [36]. A recent report by Berg and 
McBurney has stated that the density of P19 cells in the 
culture is critical in determining the efficiency of differ- 
entiation induction [37]. Our present finding that RA- 
induced granulocytic differentiation is cell cycle phase- 
dependent provides an important information in under- 
standing the regulatory control in cellular growth and 
differentiation. 
Sphingolipids participate in fundamental biological 
processes, such as cell-cell interaction, proliferation, 
differentiation, and oncogene transformation (see [38] 
for reviews). The discovery that sphingolipid-derived 
molecules, such as sphingosine and lysosphingolipids 
are potent and reversible inhibitors of PKC have 
spurred the studies of these molecules’ biological roles 
[39]. Until recently, it was demonstrated that SP, the 
saturated form of sphingosine, dramatically enhances 
RA- and other antileukemia chemotherapeutic agent- 
induced differentiation [ 13,401. In this report, we have 
further shown that SP exhibits an effect on blocking the 
cell progression through G,/S phase. The data explain 
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Fig. 3. Intracellular distribution of [‘H]RA. HL-60 cells were cultured 
in 25-cm’ plastic tissue flasks. Cells were cultured without any drugs 
in the medium (control. C) (0) or pretreated with APH (0). MIMO 
(a) or SP (x) as described in Fig. 2 before [‘H]RA (final concentra- 
tion = 1 PM) was added. After 2 h of RA incubation, the drugs were 
removed (washed three times with PBS). At various times after the 
washing procedure the uptake of [3H]RA into the cells (A) was deter- 
mined. At 0 h (B) or 18 h (C) after washing procedure, cell fractiona- 
tion was carried out, the distribution of [ZH]RA was determined as 
described in section 2.10. Points = mean; bars = S.D. (n = 3). 
why SP can potentiate the RA-induced differentiation. 
SP regulates the induction of differentiation by allowing 
cells to accumulate in an extended GJS phase. The GJS 
phase is the period in the cell cycle at which RA has the 
greatest effect on induction of differentiation. Further- 
more, the present study of [3H]RA accumulation and 
distribution has indicated that the potentiation of RA- 
induced differentiation by G,/S blocker cannot be sim- 
ply explained by the extent of accumulation and differ- 
ential distribution of RA in cells that had or had not 
been pretreated with SP, MIMO or APH. Some other 
important factors probably exist in G,/S phase, playing 
a critical role in the regulation of the induction of differ- 
entiation. 
The molecular events involved in this cell cycle phase- 
dependent effect of RA are not understood. These types 
of studies are under current investigation. Expression of 
some cell cycle specific genes and enzymatic activity 
(such as PKC) during the induction of differentiation 
may provide instructive clues. Compounds that perturb 
the cell cycle at or near the G,/S phase boundary may 
allow the identification of the key transcriptional and 
posttranscriptional processes that regulate the initiation 
of DNA synthesis and cellular differentiation in cells. 
Our present study may have important therapeutic 
implications. Following drug administration, the circu- 
lating and plasma concentrations decline as the excre- 
tion processes take place. Exposure of the tumor to RA 
for a short period of time may not be effective enough 
to control the leukemia growth. Our finding that pre- 
treatment with SP can increase the percentage of cells 
differentiated by brief RA treatment and the finding of 
the cell cycle phase-dependent effect of RA suggests that 
RA therapy can be largely improved by co- or pre- 
treatment with appropriate modulator of cell cycle pro- 
gression. 
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